Our purpose is to invest to extend and enhance human life ABOUT US BUILDING THE NEXT GENERATION OF GLOBAL LEADERS IN LIFE SCIENCE We found, build and fund companies to translate exceptional science into transformational treatments for patients in areas of high unmet need. WHO WE ARE Syncona domain expertise Our deep expertise in four key modalities enables the rapid translation of scientific research into companies with the potential to be global leaders and the development of a diversified portfolio of 15-20 companies Cell therapy Gene therapy Biologics Small molecule EXPLORE OUR PORTFOLIO Delivering sustainable value We are focused on maximising value at all points of the investment cycle to deliver transformational treatments to patients, capture superior risk adjusted returns for shareholders and build long term value for all stakeholders. INVESTORS SYNC (LON) 214.00 GBX CHANGE -4.00 (-1.83%) 29 November 2021 at 01:35. Pricing delayed by 20 mins. Making a positive contribution We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families. SUSTAINABILITY Latest videos 1 / 6 Syncona CEO Martin Murphy discusses Clade Series A financing 03.11.21 | VIDEO LENGTH 10:16 Anaveon doses first patient 24.06.21 | VIDEO LENGTH 6:18 Introduction to Richard Francis, Chief Executive of Purespring Therapeutics 11.02.21 | VIDEO LENGTH 3:42 Introduction from Quell Therapeutics, CEO, Iain McGill 11.02.21 | VIDEO LENGTH 5:38 VIEW ALL VIDEOS Latest insights 1 / 6 03.11.21 Syncona CEO Martin Murphy discusses Clade Series A financing FOUND, BUILD, FUND CELL THERAPY CLADE THERAPEUTICS 22.10.21 Freddie Dear discusses why biopharma’s current macro trends mean that now is an opportune time to invest in biotech LIFE SCIENCE INDUSTRY SYNCONA 24.09.21 Alex Hamilton on manufacturing in cell and gene therapy and the role of development partnerships LIFE SCIENCE INDUSTRY SYNCONA VIEW ALL INSIGHTS AND ARTICLES Latest news 1 / 6 15.11.21 Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director CELL THERAPY AUTOLUS 12.11.21 Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting BIOLOGICS ANAVEON 12.11.21 Achilles Therapeutics Presents Data at the SITC Annual Meeting OPERATING NEWS CELL THERAPY ACHILLES THERAPEUTICS VIEW ALL NEWS Annual Report and Accounts 2021 Our 2021 Annual Report and Accounts provides an overview of our most recent financial year, as we look to deliver on behalf of our stakeholders. 01.07.21 | PDF (8.00MB) DOWNLOAD An expert multi-disciplinary team, attracting world-class talent We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients. OUR PEOPLE LEADERSHIP KEY FACTS* 14 members of the investment team 240+ years of life science and investment expertise 79% investment team with PhDs *All as of 31 March 2021 Sign-up for company news alerts Get the latest RNS, company news, share price information and results from Syncona RNS ALERTS COMPANY ALERTS Contact Syncona Investment Management Limited 2nd Floor 8 Bloomsbury Street London WC1B 3SR contact@synconaltd.com Explore About us Our people Portfolio Sustainability News and Insights Investors Contact Copyright © Syncona 2021 Accessibility Privacy & cookies Employee privacy notice Third party privacy notice Regulatory publications Modern Slavery Statement Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD. Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited. Designed & built by SampsonMay Accept to continue or find out more in our cookie policy. Change settings ACCEPT AND CLOSE